Related Experiment Video
Updated: May 21, 2025

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats
Published on: June 28, 2019
The Novel A-Flux Coronary Sinus Reducer Normalizes Coronary Microvascular Function in a Persistently Symptomatic
Giovanni Occhipinti1, Anthony Salazar-Rodriguez1, Francesco Giannini2
1Hospital Clínic, Cardiovascular Clinic Institute, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
Abstract:
Coronary microvascular dysfunction (CMD) contributes to persistent angina/anginal equivalent symptoms and is associated with adverse outcomes. Coronary sinus reduction (CSR) is a device-based therapy with the potential to improve outcomes by reducing symptom burden and improving coronary flow reserve. A patient with CMD underwent CSR with the next-generation A-Flux device.
More Related Videos
05:07Author Spotlight: Improved Localization and Monitoring of Coronary Flow Reserve Using Modified PLAX View in Mice
Published on: August 25, 2023
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017